212. Increasing frequency of multi-resistance Pseudomonas aeruginosa in critical patients in Colombia
Session: Poster Abstract Session: Antimicrobial Resistance: Clinical Studies
Friday, October 21, 2011
Room: Poster Hall B1
Background: 

Pseudomonas aeruginosa is an important microorganisms frequently found in hospital acquired infections in critical patients

Methods: 

A surveillance network with 33 third level hospitals in 5 cities in Colombia submitted monthly laboratory information between january 2005 and december 2009. CLSI 2009 rules were used. Resistance rates of first isolates of any type of sample from patients in the intensive care unit (ICU) were analyzed.

Results: 

3558 isolates of P. aeruginosa were processed (5,3% of all isolates). A resistance rate over 20% against all antibiotics tested were found, except for amikacin. During the study time the resistance rates increased for piperacillin/tazobactam, cefepime, and imipenem; it remained unchanged for meropenem, and decreased for aminoglycosides, quinolones and ceftazidime. Resistance to one, two and three or more families of antibiotics was found in 5.3%, 12.5%, and 32.1% and increased over time.

Conclusion: 

Resistance to antibiotics in isolates of P. aeruginosa in critical patients in Colombia is high and increased in the last years. There is a high number of multi-resistant isolates. A call for antibiotic stewardship and infection control is done in critical patients.


Subject Category: A. Antimicrobial agents and Resistance

Lina Villa, MD1, Jorge Cortes, MD2, Aura Leal, MSc MD3 and Andres Meneses, MD1, (1)Universidad Nacional de Colombia, Bogota, Colombia, (2)Medicine, Universidad Nacional de Colombia, Bogota, Colombia, (3)Universidad Nacional de Colombia, Bogotá, Colombia

Disclosures:

L. Villa, None

J. Cortes, Pfizer: Grant Investigator, Educational support and Research support
Merck: Grant Investigator, Educational support and Research support

A. Leal, Merck: Grant Investigator, Research grant

A. Meneses, None

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.